Thank you, Madam Chair.
I'd like to thank the guests for coming. I'm going to try to rapid-fire my questions so that I can get them all in.
What I'm hearing from my colleagues is really the balance between risk and benefit. If you have an approval process that's too long, there would be an adverse event in not providing access to drugs to the people who need it. That's a bad thing in itself, but you don't want it to be so fast that you're putting the population at risk. That's a tough thing to do.
The Standing Committee on Health just completed a study on the common drug review, as I'm sure you all know. What role, if any, would you expect the common drug review to have in relation to the life cycle of any particular drug, and what effect will Health Canada's proposal with the life cycle approach to drug safety have on the common drug review?
As well, how do you propose to deal with different indicators? Once a drug is in the market and it's found to help another ailment, how does that work? And how do you propose to deal with those types of situations?